COMP <GO>
MMED vs UNH // RSI-14 & 200D SMA MOMENTUM
MiniMed Group Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: MMED 3
— UNH 11
▲ RSI-14 & 200D SMA MOMENTUM LEADER: UNH
LAST: $18.28 (-5.04%) • MKT CAP: $5.42B
rsi-technicals
43.8
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
rsi-technicals
56.0
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MMED VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MMED | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.20% | 88.57% | -34.37 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | 11.47% | -15.37 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.75% | 6.48% | -14.23 | UNH | /fcf-yield <GO> |
| Operating Margin | -6.10% | 4.82% | -10.92 | UNH | /operating-margins <GO> |
| Net Profit Margin | -10.70% | 3.14% | -13.84 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 14.30% | 6.46% | +7.84 | MMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.82 | 3.12 | +1.70 | MMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.74% | +0.36 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 43.8 | 56.0 | -12.23 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.33 | +0.72 | MMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 17.1x | +6.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.42B | $364.66B | -$359.24B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MMED REV | UNH REV | MMED GROSS % | UNH GROSS % | MMED FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.10B | $447.57B | 54.2% | 88.7% | -$420.0M | $16.07B |
| FY 2024 | $2.71B | $400.28B | 56.3% | 88.3% | -$53.0M | $20.70B |
| FY 2023 | $2.47B | $371.62B | 44.0% | 89.6% | -$70.1M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MMED // BETA 1.05
UNH // BETA 0.33